Sector News

Gilead’s ‘open to suggestion’ on its next big M&A splash

May 1, 2015
Life sciences
On pace to reap $29 billion in revenue this year thanks to its surging hepatitis C franchise, Gilead Sciences has the cash to pull off a big deal or two, and management is eyeing a slew of late-stage opportunities.
 
The Big Biotech wowed analysts with a $7.6 billion sales quarter, good for 52% annual growth, leading to an obvious question: What’s Gilead going to do with all that money? Expand its pipeline, R&D chief Norbert Bischofberger said on a conference call, pointing to “myriad external possibilities” out there on the market.
 
Gilead has largely shied away from big-ticket dealmaking since its $11 billion acquisition of Pharmasset–from which it acquired the then-inchoate hep C blockbusters Sovaldi and Harvoni. But, thanks in part to its bountiful cash flow, the company is now more agnostic about deal size, President and COO John Milligan said, worrying less about price than whether a target is “the right fit for Gilead.”
 
“We typically like things where we can have impact on Phase III and where we can accelerate those products either into the approval process or into greater indications after the approval process,” Milligan told analysts. “… So, we’re open to suggestion–there have been many mentioned out there–but I would say that I want to stick very closely to kinds of (therapeutic) areas we’re in here today.”
 
That likely means more asset-minded deals, like Gilead’s $600 million buyout of the cancer biotech Calistoga Pharmaceuticals or its $470 million partnership with the NASH-focused Phenex Pharmaceuticals.
 
But, walking back comments made last year, Gilead is no longer ruling out major M&A.
 
And, as Milligan mentioned, analysts are happy to suggest just where Gilead should direct its checkbook. Bernstein’s Geoffrey Porges has urged the company to take a $45 billion plunge on Vertex Pharmaceuticals to get a foothold in orphan drugs, and other analysts have pointed to NASH leader Intercept Pharmaceuticals, which has a market cap of roughly $6 billion.
 
By Damian Garde
 

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach